These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 22903389

  • 1. Pharmacological effects of cannabinoids on the reference and working memory functions in mice.
    Avdesh A, Hoe Y, Martins RN, Martin-Iverson MT.
    Psychopharmacology (Berl); 2013 Jan; 225(2):483-94. PubMed ID: 22903389
    [Abstract] [Full Text] [Related]

  • 2. Cannabinoid-induced working memory impairment is reversed by a second generation cholinesterase inhibitor in rats.
    Braida D, Sala M.
    Neuroreport; 2000 Jun 26; 11(9):2025-9. PubMed ID: 10884065
    [Abstract] [Full Text] [Related]

  • 3. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
    McMahon LR, Koek W.
    Eur J Pharmacol; 2007 Aug 13; 569(1-2):70-6. PubMed ID: 17553486
    [Abstract] [Full Text] [Related]

  • 4. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
    McMahon LR.
    Psychopharmacology (Berl); 2006 Oct 13; 188(3):306-14. PubMed ID: 16953389
    [Abstract] [Full Text] [Related]

  • 5. CB1 receptor-mediated signaling underlies the hippocampal synaptic, learning, and memory deficits following treatment with JWH-081, a new component of spice/K2 preparations.
    Basavarajappa BS, Subbanna S.
    Hippocampus; 2014 Feb 13; 24(2):178-88. PubMed ID: 24123667
    [Abstract] [Full Text] [Related]

  • 6. Apparent Affinity Estimates and Reversal of the Effects of Synthetic Cannabinoids AM-2201, CP-47,497, JWH-122, and JWH-250 by Rimonabant in Rhesus Monkeys.
    Hruba L, McMahon LR.
    J Pharmacol Exp Ther; 2017 Aug 13; 362(2):278-286. PubMed ID: 28533288
    [Abstract] [Full Text] [Related]

  • 7. Hippocampal CB(1) receptors mediate the memory impairing effects of Delta(9)-tetrahydrocannabinol.
    Wise LE, Thorpe AJ, Lichtman AH.
    Neuropsychopharmacology; 2009 Aug 13; 34(9):2072-80. PubMed ID: 19322169
    [Abstract] [Full Text] [Related]

  • 8. Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice.
    McMahon LR, Ginsburg BC, Lamb RJ.
    Psychopharmacology (Berl); 2008 Jul 13; 198(4):487-95. PubMed ID: 17673980
    [Abstract] [Full Text] [Related]

  • 9. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.
    Janoyan JJ, Crim JL, Darmani NA.
    Pharmacol Biochem Behav; 2002 Jul 13; 71(1-2):155-62. PubMed ID: 11812518
    [Abstract] [Full Text] [Related]

  • 10. Cannabinoid CB(1) antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats.
    Fattore L, Spano S, Cossu G, Deiana S, Fadda P, Fratta W.
    Neuropharmacology; 2005 Jun 13; 48(8):1097-104. PubMed ID: 15910886
    [Abstract] [Full Text] [Related]

  • 11. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.
    Darmani NA.
    Neuropsychopharmacology; 2001 Feb 13; 24(2):198-203. PubMed ID: 11120402
    [Abstract] [Full Text] [Related]

  • 12. CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents.
    Haller J, Varga B, Ledent C, Freund TF.
    Behav Pharmacol; 2004 Jul 13; 15(4):299-304. PubMed ID: 15252281
    [Abstract] [Full Text] [Related]

  • 13. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions.
    Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, Maffrand JP, Le Fur G, Casellas P.
    J Biol Chem; 1997 Aug 29; 272(35):22330-9. PubMed ID: 9268384
    [Abstract] [Full Text] [Related]

  • 14. SR 141716A enhances spatial memory as assessed in a radial-arm maze task in rats.
    Lichtman AH.
    Eur J Pharmacol; 2000 Sep 15; 404(1-2):175-9. PubMed ID: 10980277
    [Abstract] [Full Text] [Related]

  • 15. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
    McMahon LR.
    J Pharmacol Exp Ther; 2006 Dec 15; 319(3):1211-8. PubMed ID: 16943255
    [Abstract] [Full Text] [Related]

  • 16. Cannabinoid modulation of rat pup ultrasonic vocalizations.
    McGregor IS, Dastur FN, McLellan RA, Brown RE.
    Eur J Pharmacol; 1996 Oct 10; 313(1-2):43-9. PubMed ID: 8905327
    [Abstract] [Full Text] [Related]

  • 17. Cannabinoid-induced tolerance is associated with a CB1 receptor G protein coupling switch that is prevented by ultra-low dose rimonabant.
    Paquette JJ, Wang HY, Bakshi K, Olmstead MC.
    Behav Pharmacol; 2007 Dec 10; 18(8):767-76. PubMed ID: 17989514
    [Abstract] [Full Text] [Related]

  • 18. SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity.
    Pan X, Ikeda SR, Lewis DL.
    Mol Pharmacol; 1998 Dec 10; 54(6):1064-72. PubMed ID: 9855635
    [Abstract] [Full Text] [Related]

  • 19. The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats.
    Lichtman AH, Martin BR.
    Pharmacol Biochem Behav; 1997 Dec 10; 57(1-2):7-12. PubMed ID: 9164547
    [Abstract] [Full Text] [Related]

  • 20. Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats.
    Lichtman AH, Dimen KR, Martin BR.
    Psychopharmacology (Berl); 1995 Jun 10; 119(3):282-90. PubMed ID: 7675962
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.